PCV13: Effective Against First-Episode CAP in Older Adults

Slideshow

The 13-valent pneumococcal conjugate vaccine reduced nearly by half vaccine-type community acquired pneumonia in adults aged 65 years and older.

Recent Videos
Tezepelumab Significantly Reduced Exacerbations in Patients with Severe Asthma, Respiratory Comorbidities
Interview with Kelly Moore, MD, MPH, president, chief executive officer, Immunization Action Coalition
Related Content
Omlyclo Gains FDA Approval as Interchangeable Omalizumab Biosimilar: Daily Dose / image credit: ©New Africa/AdobeStock

Omlyclo Gains FDA Approval as Interchangeable Omalizumab Biosimilar: Daily Dose

Sydney Jennings
March 24th 2025
Article

Your daily dose of the clinical news you may have missed.

Respiratory Tripledemic 2022-23: An Expert Recap

Respiratory Tripledemic 2022-23: An Expert Recap

Sydney Jennings
April 6th 2023
Podcast

William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.

FDA Approves Omlyclo as First Interchangeable Omalizumab Biosimilar

FDA Approves Omlyclo as First Interchangeable Omalizumab Biosimilar

Patient Care Editorial Staff
March 10th 2025
Article

Omlyclo is indicated for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, IgE-mediated food allergy, and chronic spontaneous urticaria.

NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half

NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half

Sydney Jennings
May 20th 2022
Podcast

In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.

Depemokimab Shows Significant Improvements in Rhinosinusitis with Nasal Polyps: New Research / Image credit: ©hapsuwanArt/AdobeStock

Depemokimab Shows Significant Improvements in Rhinosinusitis with Nasal Polyps: New Research

Sydney Jennings
March 5th 2025
Article

AAAAI 2025: Data from the ANCHOR-1 and ANCHOR-2 phase 3 trials show improvements in nasal polyp size and obstruction for depemokimab with twice-yearly dosing vs placebo.

With the Flu Season in Overdrive, Hospitals are Overwhelmed / image credit ©sudok1/stock.adobe.com

With the Flu Season in Overdrive, Hospitals are Overwhelmed

Ron Southwick
February 12th 2025
Article

Some hospitals have EDs filled with patients and a number of states are reporting the 2024-2025 version of a COVID-19, flu, and RSV tripledemic.

© 2025 MJH Life Sciences

All rights reserved.